Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopesDaniel J. Hui, Federico Mingozzi, David W. Scott et al.|Molecular Therapy|2013Cited by 45
Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?Anne S. De Groot, William J. Martin, Leslie P. Cousens et al.|Clinical and Developmental Immunology|2013Cited by 23
Teaching toleranceLeslie P. Cousens, Anne S. De Groot, Federico Mingozzi et al.|Human Vaccines & Immunotherapeutics|2012Cited by 18
Improved GAA activity in tregitope-treated pompe disease: preclinical studies (TECH1P.864)Leslie P. Cousens, Anne S. De Groot, Dwight D. Koeberl et al.|The Journal of Immunology|2014Cited by 0
New approaches to enzyme replacement therapy for Pompe diseaseLeslie P. Cousens, Anne S. De Groot, Federico Mingozzi et al.|Unknown|2012Cited by 0